Shanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval

Reuters03-26

Shanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval

Shanghai Pharma said its subsidiary Shanghai Hefeng Pharma received regulatory approval in China to manufacture dihydroxypropyl theophylline injection, adding a newly registered product to its portfolio.
The company reported cumulative R&D spending of CNY 3.1 million on the product, positioning it to compete in a market with multiple domestic manufacturers.
Shanghai Pharma cited IQVIA data showing 2025 mainland China hospital procurement for this injectable category totaled CNY 324.8 million, indicating a defined addressable market for potential share gains.
The approval under the newer registration classification may support reimbursement and hospital procurement access, which could influence commercialization outcomes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069114), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622853686?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622853686","market":"nz","top_or_hot":-1,"title":"Shanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Pharmaceuticals FY2025 R&amp;D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Shanghai Pharma said its subsidiary Shanghai Hefeng Pharma received regulatory approval in China to manufacture dihydroxypropyl theophylline injection, adding a newly registered product to its portfolio.\n        </li>\n<li>\n          The company reported cumulative R&amp;D spending of CNY 3.1 million on the product, positioning it to compete in a market with multiple domestic manufacturers.\n        </li>\n<li>\n          Shanghai Pharma cited IQVIA data showing 2025 mainland China hospital procurement for this injectable category totaled CNY 324.8 million, indicating a defined addressable market for potential share gains.\n        </li>\n<li>\n          The approval under the newer registration classification may support reimbursement and hospital procurement access, which could influence commercialization outcomes.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069114), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Pharmaceuticals FY2025 R&amp;D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Shanghai Pharma said its subsidiary Shanghai Hefeng Pharma received regulatory approval in China to manufacture dihydroxypropyl theophylline injection, adding a newly registered product to its portfolio.\n        </li>\n<li>\n          The company reported cumulative R&amp;D spending of CNY 3.1 million on the product, positioning it to compete in a market with multiple domestic manufacturers.\n        </li>\n<li>\n          Shanghai Pharma cited IQVIA data showing 2025 mainland China hospital procurement for this injectable category totaled CNY 324.8 million, indicating a defined addressable market for potential share gains.\n        </li>\n<li>\n          The approval under the newer registration classification may support reimbursement and hospital procurement access, which could influence commercialization outcomes.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069114), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0184","symbol_name":"上海国资改革","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8n5ZFt:1","article_id":"2622853686","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622853686","pubTimestamp":1774517521,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval. Shanghai Pharma said its subsidiary Shanghai Hefeng Pharma received regulatory approval in China to manufacture dihydroxypropyl theophylline injection, adding a newly registered product to its portfolio.The company reported cumulative R&D spending of CNY 3.1 million on the product, positioning it to compete in a market with multiple domestic manufacturers.Shanghai Pharma cited IQVIA data showing 2025 mainland China hospital procurement for this injectable category totaled CNY 324.8 million, indicating a defined addressable market for potential share gains.The approval under the newer registration classification may support reimbursement and hospital procurement access, which could influence commercialization outcomes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to prov","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0184":"上海国资改革","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK0183":"MSCI概念","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK0188":"融资融券","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","BK0012":"证金概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","BK0187":"一线龙头","BK4585":"ETF&股票定投概念","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK0028":"国家队","IQV":"艾昆纬","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK0175":"白马股","BK4121":"生命科学工具和服务","BK0099":"上海本地重组","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","BK0209":"零售","BK0196":"行业龙头","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","BK4588":"碎股","BK0097":"医药电商","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4530":"医药外包概念","BK0020":"浦东新区","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD"},"translate_title":"上海医药2025财年研发支出增至310万元人民币；二羟丙基茶碱注射液获NMPA生产批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"IQV":0.9},"content_text":"Shanghai Pharmaceuticals FY2025 R&D spending rises to CNY 3.1 million; dihydroxypropyl theophylline injection wins NMPA production approval\n    \n\n\n          Shanghai Pharma said its subsidiary Shanghai Hefeng Pharma received regulatory approval in China to manufacture dihydroxypropyl theophylline injection, adding a newly registered product to its portfolio.\n        \n\n          The company reported cumulative R&D spending of CNY 3.1 million on the product, positioning it to compete in a market with multiple domestic manufacturers.\n        \n\n          Shanghai Pharma cited IQVIA data showing 2025 mainland China hospital procurement for this injectable category totaled CNY 324.8 million, indicating a defined addressable market for potential share gains.\n        \n\n          The approval under the newer registration classification may support reimbursement and hospital procurement access, which could influence commercialization outcomes.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Pharmaceuticals Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12069114), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622853686","isCrawlerRequest":true}